| Novartis Pharma Schweiz AG - Cosentyx 150 mg, Pulver zur Herstellung einer Injektionslösung |
| 63295 | | 01 | | Cosentyx 150 mg | | Pulver zur Herstellung einer Injektionslösung | | L04AC10 | | Secukinumab | | 20.02.2015 | | |
|
| Composition |
| Praeparatio cryodesiccata: secukinumabum 150 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, pro vitro. |
| Packungsbestandteile |
| Praeparatio cryodesiccata: | | | Dry substance | | | | | | | | Active Agent | Dose |
|---|
| Secukinumabum | 150 mg |
| | BAG: Active Agent | Dose |
|---|
| Secukinumabum | 150 mg |
| | | | Inactive agents |
|---|
| Histidin Hydrochloride Monohydrate | | Histidine | | Polysorbatum 80 | | Saccharum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | Durchstechflasche(n) | 538.86 | 602.45 | B | SL | No |
|
